Maxim Group restated their positive rating on shares of Mesoblast limited (NASDAQ:MESO) in a research report report published on Wednesday. Maxim Group currently has a $14.00 price target on the stock.

Separately, Zacks Investment Research raised shares of Mesoblast limited from a hold rating to a buy rating and set a $6.75 price target on the stock in a report on Thursday, January 26th.

Mesoblast limited (NASDAQ:MESO) opened at 8.70 on Wednesday. The company has a 50-day moving average price of $6.57 and a 200-day moving average price of $5.30. Mesoblast limited has a one year low of $3.50 and a one year high of $10.46. The company’s market capitalization is $662.02 million.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at

Your IP Address:

A hedge fund recently bought a new stake in Mesoblast limited stock. Penbrook Management LLC purchased a new position in Mesoblast limited (NASDAQ:MESO) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 31,200 shares of the company’s stock, valued at approximately $134,000. Institutional investors own 3.14% of the company’s stock.

About Mesoblast limited

5 Day Chart for NASDAQ:MESO

Receive News & Ratings for Mesoblast limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast limited and related companies with's FREE daily email newsletter.